Q-omics provides the consensus-scored SEMA6B profile across patient tissues and cancer cell-line models. SEMA6B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SEMA6B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SEMA6B RNA expression shows 21,043 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where SEMA6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEMA6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEMA6B survival associations across molecular data types. SEMA6B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEMA6B RNA expression–survival associations across cancer types. High SEMA6B expression shows unfavorable associations in KIRP, ACC, UVM, MESO and THCA, but favorable associations in LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SEMA6B RNA expression.
This table summarizes SEMA6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SEMA6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEMA6B shows higher tumor expression in KIRC, HNSC, THCA, STAD, LIHC and CHOL. The KIRC box plot shows higher SEMA6B RNA expression in tumor versus normal tissue (log2 FC = +1.709, t-test p < 0.001).
This table shows molecular features associated with SEMA6B in patient tissues and cancer cell lines. In patient samples, SEMA6B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SEMA6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
